Can a single morning cortisol measurement establish HPA-axis hypofunction?

A morning serum cortisol is an important first-line assessment for suspected hypothalamic-pituitary-adrenal (HPA)-axis hypofunction, but its diagnostic meaning depends strongly on the result’s extremity, assay, timing, and clinical context. The categorical claim that one measurement cannot establish hypofunction is therefore too absolute.

Clinical evidence

• In suspected central adrenal insufficiency, Endocrine Society guidance considers a morning cortisol <3 μg/dL strongly suggestive of adrenal insufficiency. This can provide compelling preliminary diagnostic evidence when interpreted in the appropriate clinical setting.
• Values of 3–15 μg/dL are indeterminate and warrant corticotropin (cosyntropin) stimulation testing. Dynamic testing assesses adrenal reserve rather than relying on a single basal concentration.
• In a large retrospective cohort, a morning cortisol <10 μg/dL had 96.2% sensitivity for a subnormal cosyntropin response, supporting its use as a sensitive triage test. However, limited specificity means that this threshold cannot reliably confirm hypofunction by itself.

Interpretation and mechanisms

• Total serum cortisol reflects both biologically active free cortisol and cortisol bound to cortisol-binding globulin (CBG). Increased CBG—for example, with estrogen exposure or pregnancy—can raise measured total cortisol independently of free cortisol availability.
• Thresholds also vary with the laboratory assay, population, and the stimulated-cortisol criterion used as the reference standard. In pituitary populations, proposed “rule-in” and “rule-out” cutoffs shift with assay alignment and stimulation-test definitions.
• These factors explain why an isolated non-extreme cortisol result is an imperfect proxy for integrated HPA-axis function.

Bottom line

• A single morning cortisol can be highly informative, particularly when very low, but it does not universally establish HPA-axis hypofunction. Intermediate results—especially 3–15 μg/dL in suspected central disease—should be followed by cosyntropin stimulation testing and interpreted alongside assay characteristics and binding-protein context.